Physician profile
Lisa Anne Johnson
NPI 1679591994
$25,194.61
in general payments reported to CMS, 2019-2025
25 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $59.73 · 2023: $540 · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,941 · Travel and Lodging: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,440.00 |
| Food and Beverage | $6,941.28 |
| Travel and Lodging | $1,592.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19,894.78 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,622.18 | 2021-2025 | |
| Pfizer INC. | $447.78 | 2023-2025 | |
| Janssen Biotech, INC. | $422.49 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $399.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $329.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $305.05 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $276.80 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.07 | 2021-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $184.89 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $148.80 | 2025 | Wegovy |
| Amgen INC. | $108.46 | 2023-2025 | Repatha, Uplizna |
| Janssen Scientific Affairs, LLC | $104.11 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $100.16 | 2024-2025 | Omvoh |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2024 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.81 | 2023-2024 | Caplyta |
| Aimmune Therapeutics, INC. | $81.67 | 2024-2025 | Zenpep |
| Celgene Corporation | $74.54 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $68.40 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $61.36 | 2024-2025 | Iqirvo |
| Evoke Pharma, INC. | $51.98 | 2025 | |
| Ferring Pharmaceuticals INC. | $43.15 | 2024-2025 | Rebyota |
| Digestive Care, INC. | $33.78 | 2024 | Pertzye |
| Dexcom, INC. | $31.68 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $21.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.